Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoPharm has been notified that the US Securities and Exchange Commission has closed an investigation of the company and no enforcement action has been recommended.
Subscribe to our email newsletter
The Securities and Exchange Commission (SEC) investigation commenced in March 2004 and NeoPharm believes it concerned disclosures regarding the development of two drug candidates.
The decision of the SEC to terminate its investigation is not a finding or judgment regarding the matters investigated.
NeoPharm is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new cancer drugs for therapeutic applications. NeoPharm has built its drug portfolio based on its two novel proprietary technology platforms: a tumor-targeting platform and the NeoLipid drug delivery system.